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Abstract
Cyclic N1-pentylinosine monophosphate (cpIMP), a novel simplified inosine derivative of cyclic ADP-ribose (cADPR) in which
the N1-pentyl chain and the monophosphate group replace the northern ribose and the pyrophosphate moieties, respectively, was
synthesized. The role played by the position of the phosphate group in the key cyclization step, which consists in the formation of a
phosphodiester bond, was thoroughly investigated. We have also examined the influence of the phosphate bridge on the ability of
cpIMP to mobilize Ca2+ in PC12 neuronal cells in comparison with the pyrophosphate bridge present in the cyclic N1-pentyl-
inosine diphosphate analogue (cpIDP) previously synthesized in our laboratories. The preliminary biological tests indicated that
cpIMP and cpIDP induce a rapid increase of intracellular Ca2+ concentration in PC12 neuronal cells.
Introduction
Nucleosides and nucleotides (NNs) are widely used as key
intermediates and important core structures in the field of syn-
thetic medicinal chemistry [1,2]. They represent versatile syn-
thetic building blocks towards the synthesis of biologically rele-
vant compounds such as antiviral and antineoplastic drugs
[3-8], antibiotics and antifungal agents [9-11]. Furthermore,
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several NNs act as potent second messengers involved in the
regulation of key metabolic pathways [12]. Among these NNs
there is the cyclic ADP-ribose (cADPR 1, Figure 1), a metabo-
lite strictly involved in the homeostasis of cellular calcium ions.
cADPR is a second messenger that activates the ryanodine
receptors of the sarcoplasmic reticulum and mobilizes Ca2+ ions
in many cell types of protozoa, plants, animals and humans
[13].
Figure 1: Structures of cADPR (1), cIDPR (2), cpIDP (3) and cpIMP
(4).
Furthermore, there is a strong evidence that cADPR is an
important second messenger in the nervous system where it is
involved in the handling of Ca2+ ions that control several func-
tions. Indeed, the administration of cADPR to cell cultures
produces three patterns of response in terms of variation of
intracellular concentration of calcium ions ([Ca2+]i): (a) a rapid
response after direct microinjection of the messenger into the
cells; (b) a slow variation of [Ca2+]i when cADPR is added to
the cell culture medium; c) a progressive potentiation of [Ca2+]i
increasing due to a depolarization. In fact, cADPR induces Ca2+
release from presynaptic and postsynaptic intracellular stores
and plays an important role in the activity-dependent synaptic
plasticity, including long-term depression [14]. In addition,
enzymes able to catalyze the hydrolysis of cyclic ADP-ribose to
ADP-ribose are expressed ubiquitously in the mouse brain.
Specifically, wild-type mice show the highest cyclase activity in
the hypothalamus, and then in the cerebellum, cerebrum and
posterior pituitary [15].
Unfortunately, the lability of the N-1 glycosidic bond of
cADPR towards enzymatic and/or non-enzymatic hydrolysis to
ADP-ribose, even in a neutral aqueous solution, greatly hinders
the studies aimed at elucidating its physiological role [16].
Several enzymes involved in the metabolism of cADPR have
been described. Among them is the ubiquitous ADP-ribosyl
cyclase, an enzyme first isolated from Aplysia Californica [17].
Using the Aplysia ADP-ribosyl cyclase many metabolite
analogues of cADPR have been produced starting from NAD+
and NADP+ [18-21]. However, the specificity of the enzymatic
cyclization mechanism drastically limits its applicability for
enzymatic or chemo-enzymatic procedures. For this reason, to
obtain new cADPR derivatives the exploitation of chemical
synthetic strategies is still necessary. A lot of modifications
regarding the northern and southern ribose as well as the purine
base of cADPR have been proposed so far [22,23]. Matsuda and
co-workers were the first who synthesized new analogues of the
cADPR in which the adenine base was replaced by a hypoxan-
thine ring [24]. This kind of modification produced the cyclic
inosine diphosphate ribose (cIDPR) 2 which proved to be stable
in hydrolytic physiological conditions and showed significant
Ca2+ mobilizing activity, thus fostering the synthesis of a
variety of cIDPR analogues. In particular, the N1, N9 and
C8-substituted cIDPR were the most interesting [24-33]. In the
last few years several cIDPR analogues were also synthesized
in our laboratory [34-37]. Among these, the N1-pentyl analogue
cpIDP (3, Figure 1) [34] showed interesting activity on the
PC12 cell line previously differentiated with the Nerve Growth
Factor (NGF) (data not previously published). Starting from
these data, we here report the synthesis and the preliminary bio-
logical activity of the new cyclic N1-pentylinosine monophos-
phate (cpIMP) (4, Figure 1), in which the pyrophosphate group
of 3 was replaced by a monophosphate moiety connecting the
southern ribose with the N1-pentyl chain. The here reported
results significantly contribute to the understanding of the role
played by the pyrophosphate moiety of cADPR and cIDPR
analogues on the mobilization of Ca2+ ions. To date, such struc-
ture-activity relationship has only been poorly investigated [38-
41]. We anticipate here that compounds 3 and 4 induce the
same effect on Ca2+ mobilization in NGF-differentiated PC12
cells. In particular, both compounds produced a transient
increase of intracellular concentration of Ca2+ when added to
the cells, thus demonstrating their ability to cross the plasma
membrane.
Results and Discussion
Chemistry
The key step for the preparation of all cADPR/cIDPR analogues
is the macrocyclization via pyrophosphate bond formation,
which is usually performed by joining the two phosphate
moieties at the end of the multistep synthesis [24-29]. Similarly,
the preparation of the new cpIMP derivative 4 could be
performed by the cyclization of a monophosphate precursor via
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Figure 2: Synthetic strategies explored in the cyclization step via phosphodiester bond formation.
Scheme 1: i) (iPr)2NP(OCE)Cl, DIPEA, THF, 1 h, rt; ii) 1) 1H-tetrazole, THF, 2) t-BuOOH, 2 h, rt; iii) 1) (iPr)2NP(OCE)2, 1H-tetrazole, THF, 2 h, rt,
2) t-BuOOH, 2 h, rt; iv) TEA/pyridine, 1:1 v/v, 16 h, rt; v) activating agent (EDC in DMF or DCC in DMF or MSNT in pyridine) 16 h, rt; vi) conc. aq
NH4OH, MeOH, 50 °C, 16 h.
phosphodiester bond formation. For this purpose we investi-
gated both the possible synthetic strategies (pathways A and B,
Figure 2) in which the phosphate group (or its synthon) has
been attached either on the end of the N1-pentyl chain
(precursor A) or on the 5’-ribose position (precursor B).
At first, to obtain the cpIMP (4) we followed the synthetic
pathway A by using the strategy reported in Scheme 1 that
employed the N1-ω-hydroxypentylinosine derivative 5 as the
starting material [34]. Compound 5 was phosphorylated on the
ω-hydroxyalkyl function by using the phosphitylating chloro-
amidite agent 6. The reaction of 5 with 6 furnished the sole
regioisomer 7 equipped with the reactive phosphorous(III)
group. Unfortunately, the activation of the phosphoramidite
function with 1H-tetrazole aimed at inducing the cyclization on
the 5’-OH ribose function produced only a complex mixture.
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Scheme 2: i) DNCB, K2CO3, DMF, 4 h, 80 °C; ii) 5-aminopentan-1-ol, DMF, 16 h, 50 °C; iii) Ac2O, pyridine, 2 h, rt, iv) NH4F, MeOH, 16 h, reflux;
v) 1) (iPr)2NP(OCE)2, 1H-tetrazole, THF, 2 h, rt, 2) t-BuOOH, 2 h, rt; vi) conc. NH4OH(aq), MeOH, 50 °C, 16 h; vii) EDC, DMF; viii) TFA, H2O, 16 h, rt.
No traces of the target cyclic compound were detected after the
usual phosphorous oxidation step.
This failure prompted us to use the alternative phosphitylating
reagent bis(cyanoethyl)phosphoramidite 8, which, after the
regioselective reaction with the 5’-hydroxyalkyl function of 5
led to the phosphotriester product 9 after the phosphorous oxi-
dation with t-BuOOH. Starting from 9 we explored two syn-
thetic routes, differing for the degree of esterification at the
phosphate moiety, to achieve the cyclization of the
17-membered ring of 4. The treatment of 9 with a mixture of
triethylamine/pyridine furnished the phosphodiester product 10
in almost quantitative yield. Instead, the complete removal of
both 2-cyanoethyl groups of 9 with concentrated aqueous
ammonia gave the phosphomonoester 11. Unfortunately, neither
linear precursors 10 nor 11 underwent the expected cyclization
step, even when treated with the most common phosphate acti-
vating agents (EDC, DCC, MSNT) in very diluted conditions.
In our opinion, the target intramolecular cyclizations failed
because of the poor mobility of the 5’-OH ribose function, as
well as because of the unfavourable anti conformation of the
N-glycosidic bond induced by the presence at the N1 position of
the purine base of the bulky ω-phosphate adduct formed with
the activating agent.
For this reason, we decided to switch to the synthetic pathway B
(Figure 2), in which the monophosphate group is installed at the
5’-ribose position. This strategy, reported in Scheme 2, used as
the starting material the 5’-TBDMS-2’,3’-O-isopropylideneino-
sine (12). The protected inosine 12 was initially converted into
the N1-dinitrophenyl derivative 13, which, after reaction with
the 5-aminopentan-1-ol, furnished the N1-ω-hydroxypentylino-
sine derivative 14 [35]. This compound was acetylated on the
ω-hydroxy function (compound 15) and then deprotected on the
5’-hydroxy function thus obtaining 16. The phosphorylation of
the 5’-OH function of 16, by using the (iPr)2NP(OCE)2/
t-BuOOH system, already used in the preparation of compound
9, furnished the 5’-O-phosphotriester inosine derivative 17. The
treatment of 17 with concentrated aqueous ammonia allowed
the removal of both the OCE phosphate protecting groups
together with the acetate function, thus obtaining the key inter-
mediate 18 as triethylammonium salt after HPLC purification.
The derivate 18, dissolved in DMF at the final concentration of
2 mM was treated with EDC (1.2 equiv) and the reaction
allowed to stand at room temperature for 48 h. From this mix-
ture it was possible to isolate cyclic compound 19 (30% cycliza-
tion yield) whose structure was confirmed by NMR and high-
resolution mass analyses. Eventually, the treatment of com-
pound 19 with aqueous 20% TFA afforded the target com-
pound 4.
Ca2+-mobilizing activity of 3 and 4 in PC12
cells
To study the biological activity of compounds 3 and 4, we eval-
uated their effect on the mobilization of Ca2+ ions in PC12 cells
differentiated with NGF. Interestingly, compounds 3 and 4
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Figure 3: Effect of 3 and 4 on intracellular [Ca2+] in NGF-differentiated PC12 cells. (A) and (B): representative single-cell traces of the effect of 3 and
4 (100 nM) on [Ca2+]i,. (C): quantification of [Ca2+]i increase calculated, after the addition of each compound, as the percentage change of plateau/
basal value. Each bar represents the mean (±S.E.M.) of the values obtained in three independent experimental sessions. For each experiment, 10 to
40 individual cells were monitored. *, P < 0.05 versus basal level.
caused a rapid and transient increase of the intracellular [Ca2+]
([Ca2+]i) when added to the medium at the concentration of
100 nM (Figure 3). This pattern of response could be ascribed
to the initial release of Ca2+ ions from the intracellular
organelles followed by a depolarization-induced Ca2+ influx.
The biological assays also confirmed that the cIDPR analogues
3 and 4 retained the ability to pass the plasma membrane of
neuronal cells.
Conclusion
cADPR is a second messenger synthesized by neuronal cells
that modulates the Ca2+ homeostasis in the nervous system
[42]. Unfortunately, cADPR is characterized by a low ability to
cross the plasma membranes. This behaviour hinders the studies
on the effects of cADPR on cell functions. To overcome this
limitation and to understand the role played by the pyrophos-
phate bridge on the biological activities of cADPR, we synthe-
sized the lipophilic derivative cpIMP (4) in which the pyrophos-
phate group of 3 was replaced by a monophosphate moiety
connecting the southern ribose with the N1-pentyl chain. We
compared the activity of 4 in modulating the concentration of
[Ca2+]i with that of the previously synthesized cpIDP (3). To
study the effect of 3 and 4 on [Ca2+]i, these compounds were
added to PC12 cells previously differentiated with NGF at the
concentration of 100 nM. Both compounds caused a fast and
transient increase in [Ca2+]i. This pattern of response could be
ascribed to the initial release of Ca2+ from intracellular
organelles followed by a depolarization-induced Ca2+ influx.
The reported preliminary results indicate that 3 and 4 possess
almost the same activity, thus indicating that the role of the
pyrophosphate bridge is not stringent and that the introduction
of an alkyl chain in the N1 position of the purine base improves
the permeation of the cell membrane by passive diffusion or
through an active uptake system expressed on the membrane.
Experimental
General
All solvents were dried by standard methods and all reactions
were carried out under inert atmosphere (argon or nitrogen). All
reagents were obtained and used from commercial sources
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(Sigma-Aldrich, Germany) without further purification. 1H and
13C NMR experiments were performed using a Varian Mercury
Plus 400 MHz spectrometer in CD3OD, D2O, CDCl3 and
acetone-d6 solvents. Chemical shifts are reported in parts per
million (δ) relative to residual solvents signals: CD2HOD 3.31,
HOD 4.80, (CD3)(CD2H)CO 2.09 for 1H NMR and CD3OD
49.0 for 13C NMR. 31P NMR experiments were carried out on a
Varian Unity INOVA 500 MHz instrument in CD3OD solvent
using 85% H3PO4 as an external standard (0 ppm). High perfor-
mance liquid chromatography (HPLC) was performed using a
Jasco UP-2075 Plus pump equipped with a Jasco UV-2075 Plus
UV detector and a 4.8 × 150 mm C-18 reversed-phase column
(particle size 5 µm) eluted with a linear gradient of CH3CN in
0.1 M triethylammonium bicarbonate (TEAB) buffer (from 0 to
50% in 45 min, flow 1.3 mL/min). UV spectra were recorded on
a Jasco V-530 UV spectrophotometer. High-resolution MS
spectra were recorded on a Bruker APEX II FT-ICR mass spec-
trometer using the electrospray ionization (ESI) technique.
Column chromatography was carried out on silica gel-60
(Merck, 0.063–0.200 mm) or on C-18 reversed-phase silica gel-
60 (Merck, 0.040–0.063 mm). Analytical TLC analyses were
performed using F254 silica gel plates (0.2 mm thick, Merck).
TLC spots were detected under UV light (254 nm).
Cell cultures and [Ca2+]i measurements
PC12 cells, grown on plastic dishes in RPMI medium composed
of 10% horse serum, 5% FBS, 100 UI/mL penicillin and
100 μg/mL streptomycin, were differentiated in neurons with
NGF (50 ng/mL; 7 days). Cells were cultured in an atmosphere
of 5% CO2. The culture medium was changed every 2 days. For
microfluorimetric studies with Fura 2-AM, cells were seeded on
glass coverslips (Fisher, Springfield, NJ, USA) coated with
poly-L-lysine (5 μg/mL) (Sigma, St. Louis, Missouri, USA) and
used at least 12 h after seeding. Intracellular Ca2+ concentra-
tion ([Ca2+]i) was measured by single cell computer-assisted
video QImaging [43]. Briefly, differentiated PC12 cells cultured
on poly-L-lysine-coated glass coverslips were loaded with
10 µM Fura-2AM for 1 h at 22 °C in Krebs–Ringer saline solu-
tion containing the following: 5.5 mM KCl, 160 mM NaCl,
1.2 mM MgCl2, 1.5 mM CaCl2, 10 mM glucose, and 10 mM
HEPES-NaOH, pH 7.4. At the end of the loading period, the
coverslips were placed in a perfusion chamber (Medical
System, Greenvale, NY, USA), mounted on a Zeiss Axiovert
200 microscope (Carl Zeiss, Germany) equipped with a FLUAR
40X oil objective lens. The experiments employed a digital
imaging system composed of a MicroMax 512BFT cooled CCD
camera (Princeton Instruments, Trenton, NJ, USA), LAMBDA
10-2 filter wheeler (Sutter Instruments, Novato, CA, USA), and
Meta-Morph/MetaFluor Imaging System software (Universal
Imaging, West Chester, PA, USA). After loading, the cells were
illuminated alternately at 340 and 380 nm by a Xenon lamp.
The emitted light was passed through a 512 nm barrier filter.
Fura-2AM fluorescence intensity was measured every 3 s. Forty
to sixty-five individual cells were selected and monitored simul-
taneously from each cover slip. Results are presented as the
cytosolic Ca2+ concentration. Calibrations used the relation of
Grynkiewicz et al. [44] assuming that the KD for Fura-2AM
was 224 nM.
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